Hey and Kimmelman • The Risk-Escalation Model Spencer Phillips Hey and Jonathan Kimmelman The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials - Terminology model - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-07-03 12:23:08 Clinical pharmacology Clinical research Design of experiments Epidemiology Medical terminology Clinical trial Therapeutic index Adverse effect Chemotherapy Amyotrophic lateral sclerosis Experimental cancer treatment		Hey and Kimmelman • The Risk-Escalation Model Spencer Phillips Hey and Jonathan Kimmelman The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials Add to Reading List Source URL: kiej.georgetown.edu Download Document from Source Website File Size: 1,70 MB Share Document on Facebook

	Rapid, automated immunoassay for atazanavir in plasma and cerebrospinal fluid (CSF) using the ARK ATV-TestTM Michael K. Helms, PhD, MBA ARK Diagnostics, Inc. 7th International Workshop on Clinical Pharmacology of HIV The DocID: 1viL6 - View Document
	Epilepsy Research Group Clinical pharmacology of antiepileptic drugs Challenges To improve our knowledge for better antiepileptic drug treatment of the individual patient. Pharmacoepidemiological studies of antiepileptic DocID: 1uXCJ - View Document
	APPLICATION FOR ACCREDITATION OF A CLINICAL PHARMACOLOGY FELLOWSHIP PROGRAM Send completed application, electronic copies (email or CD) of all documents and fee to: DocID: 1ux80 - View Document
	Clinical pharmacology and Pharmacogenomics Challenges Patients respond highly variably to drug therapy. The reason may be pharmacokinetic and/or pharmacodynamic differences between patients, due to differences in metabol DocID: 1uw1R - View Document
	Penn State University Youth Program Health Services Medical Treatment Authorization This form must be completed and returned before youth camp/program/event enrollment dates in order for youth to be permitted to particip DocID: 1rtZA - View Document